has been cited by the following article(s):
|
[1]
|
Capecitabine in advanced hepatocellular carcinoma: A multicenter experience
Digestive and Liver Disease,
2019
DOI:10.1016/j.dld.2019.06.015
|
|
|
|
|
[2]
|
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
Journal of Cancer Research and Clinical Oncology,
2018
DOI:10.1007/s00432-017-2556-6
|
|
|
|
|
[3]
|
Safety and Efficacy of Continuous Low-dose Doxorubicin and Fluorouracil (5FU) with Best Supportive Care Compared to Best Standard of Care alone for Patients with Advanced Hepatocellular Carcinoma
International Journal of Cancer and Oncology,
2017
DOI:10.15436/2377-0902.16.1194
|
|
|
|
|
[4]
|
Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma
Korean Journal of Clinical Oncology,
2016
DOI:10.14216/kjco.16006
|
|
|
|